All In Biotech

Drug Trial Radar · NCT07222488

A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)

Phase 1/2 Study of Intravesical MK-3120 in BCG-Naïve or BCG-Exposed High-Risk Non-muscle Invasive Bladder Cancer

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Dec 9, 2025

Primary completion

Jul 30, 2027

Study completion Feb 28, 2029

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder and has not spread to the bladder muscle or outside of the bladder. In standard treatment for HR NMIBC, doctors first remove the tumor with a procedure called transurethral resection of the bladder tumor (TURBT). Researchers want to learn if using MK-3120, the study medicine, can treat HR NMIBC after TURBT. The goal of this study is to learn about the safety of MK-3120 and if people tolerate it.

Conditions

  • Bladder Cancer
  • Urinary Bladder Neoplasms

Interventions

  • MK-3120Biological

    Intravesical administration at one of three doses per protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience a Dose-limiting Toxicity (DLT)Time frame: Up to approximately 5 weeks
  2. Number of Participants Who Experience One or More Adverse Events (AEs)Time frame: Up to approximately 24 months
  3. Number of Participants Who Discontinue Study Treatment Due to AEsTime frame: Up to approximately 12 months

Locations

17 sites in 12 countries. Site status is shown where the registry gives one.

  • Michael G Oefelein Clinical Trials ( Site 0005)

    Bakersfield, California · Completed

  • Rutgers Cancer Institute of New Jersey ( Site 0007)

    New Brunswick, New Jersey · Recruiting

  • Carolina Urologic Research Center ( Site 0006)

    Myrtle Beach, South Carolina · Recruiting

  • Urology Austin, PLLC ( Site 0008)

    Austin, Texas · Completed

  • Medizinische Universität Wien ( Site 0021)

    Vienna, State of Vienna, Austria · Completed

  • UZ Gent ( Site 0031)

    Ghent, Oost-Vlaanderen, Belgium · Recruiting

  • CHU de Quebec - Hopital de l'Enfant-Jesus ( Site 0011)

    Québec, Quebec, Canada · Recruiting

  • Gustave Roussy ( Site 0041)

    Villejuif, Val-de-Marne, France · Recruiting

  • European Interbalkan Medical Center ( Site 0051)

    Thessaloniki, Greece · Active not recruiting

  • Rabin Medical Center ( Site 0062)

    Petah Tikva, Israel · Recruiting

  • Centro Ricerche Cliniche di Verona ( Site 0072)

    Verona, Veneto, Italy · Recruiting

  • Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 0081)

    Amsterdam, North Holland, Netherlands · Active not recruiting

  • Akershus Universitetssykehus ( Site 0091)

    Lorenskog, Akershus, Norway · Recruiting

  • Hospital Universitario Virgen de la Victoria ( Site 0111)

    Málaga, Andalusia, Spain · Recruiting

  • Hospital Universitario 12 de Octubre ( Site 0112)

    Madrid, Madrid, Comunidad de, Spain · Recruiting

  • Ankara University Health Practice and Research Hospitals ( Site 0132)

    Ankara, Turkey (Türkiye) · Recruiting

  • Koc Universitesi Hastanesi ( Site 0133)

    Istanbul, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.